Sigma Tau Group of Italy has received the European Medicines Agency (EMA) approval for Eurartesim (dihydroartemisinin-piperaquine: DHA-PQP), the first artemisinin-based combination therapy (ACT), for the treatment of uncomplicated malaria. The product was developed in collaboration with the nonprofit research community Medicines for Malaria Venture (MMV). The product will be launched in various countries soon.
The EMA of the approved Eurartesim is now ready for delivery to Cambodia, the first country affected by malaria, which has ordered the newly approved treatment. Cambodia prioritized the use of DHA-PQP as first-line and waited for the approval of the EMA to the procurement of this product using international donor funds allow.
In the standard treatment guidelines for the World Health Organization DHA-PQP was recommended as a highly effective ACT for the treatment of uncomplicated malaria. early June ranged Eurartesim Sigma Tau for pre-qualification for the World Health Organization. This process is for donors and countries affected by malaria is an important criterion for quality and effectiveness of new drugs. In addition, Sigma Tau extends the drug for approval now in key African countries such as Burkina Faso , Mozambique, Tanzania and Ghana one.
Professor Trevor Jones, member of the Board of Directors of Sigma-Tau Group says: “Eurartesim is a great innovation in the fight against malaria, we are pleased to announce that we will continue to affect the approval and distribution of this drug in countries affected by malaria and in which thousands of people die each year from the disease, work. We also guarantee the availability in Europe.”
Although malaria-affected countries are at the forefront, Sigma Tau plans to market approval by the introduction of the EMA Eurartesim within Europe for use by travellers to or from countries affected by malaria. Eurartesim is already in pharmacies in France, Great Britain, Germany, Belgium and Portugal available, where the number of cases in Europe is highest.
MMV Eurartesim has named the project in 2011 and realized that its important contribution to the world as a quality-assured, effective medicine to cure malaria.
Sigma-Tau is an international pharmaceutical company in the research, development and commercialization of innovative investment and effective treatments to improve human well-being and quality of life.